See other companies on Welcome to the Jungle
Ezra
Full body MRIs for cancer detection
- 21-100 employees
- B2B
- Artificial Intelligence
- Deep Tech
- MedTech
- Rose Hill, New York, NY
Jump to section
Company mission
To detect cancer early for everyone in the world.
Our take
Ezra is a MedTech company that has developed a full-body screening service that spots the warning signs of cancer and other diseases in up to 13 organs. With an initial processing time of just one hour, the company rolled out the world's first 30 minute full body MRI. Ezra also schedules annual appointments for its Magnetic Resonance Imaging scans.
Ezra partners its technology with medical centers across the US and surpasses rival medical hardware creators with its use of AI, implemented in 2021. Ezra Reporter is an AI-driven solution that translates the findings from radiology reports for physicians, saving time and money in analysis. Ezra’s 2020 Series A funding went towards launching its Reporter service.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Stock options available for all employees
- Generous vacation policy
- Medical, Dental and Vision healthcare coverage for you and your family
- Wellness and commuter benefits
- Healthy food and snacks
- Offsites and happy hours
Company values
- Champion the mission: Everything we do should relate back to early cancer screening
- Think like an entrepreneur: Take ownership of your responsibilities, Collaborate, use data to make decisions, and never give up
- Obsess over the customer experience: Spend all your energy and resources delighting our customers
- Focus on quality: Given that we are literally dealing with life & death, we must deliver quality in absolutely everything we do
- Be honest: Startups are hard. Be honest with yourself, your team, our customers, and our investors
Funding (last 2 of 4 rounds)
Feb 2024
$21m
EARLY VC
Jun 2020
$18m
SERIES A
Total funding: $58.8m
This company has top investors
Leadership
Emi Gal
(CEO & CTO)Previously CEO then Board Advisor at Teads.tv and Brainient.